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No associations between prediabetes and CIND were detected in either cohort. 
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I n t r o d u c t i o n  
 
I. Diabetes  
Type 2 diabetes (hereafter, diabetes) is a chronic, progressive disorder characterized by persistently 
elevated levels of glucose in the blood (i.e. hyperglycemia).1 Diabetes is a highly multifactorial 
disease, and hyperglycemia can arise from one or several mechanisms: (i) reduced insulin secretion 
from pancreatic beta cells, (ii) increased glucagon secretion from pancreatic alpha cells, (iii) increased 
glucose production in the liver, (iv) increased lipolysis, (v) increased glucose reabsorption in the 
kidneys, (vi) reduced incretin effect in the small intestine, (vii) impaired glucose uptake in skeletal 
muscle, liver, and fat, and (viii) neurotransmitter dysfunction and brain insulin resistance.2  
An individual’s risk of developing diabetes is attributed roughly equally to environmental exposures 
(e.g. physical inactivity, excess food intake, poor nutritional quality) and genetics.3 Advanced age is 
another major risk factor for diabetes.1,4 
Prevalence and cost of diabetes 
An estimated 425 million people worldwide live with diabetes, including 58 million in Europe and 
500 thousand in Sweden.4 Overall diabetes affects 8.8% of the global adult (20-79 years) population 
and 9.6% of the global population over the age of 65.4 Since diabetes is asymptomatic in the early 
stages, approximately half of all diabetes cases are undiagnosed and therefore untreated.4  
Due to the aging global population – combined with shifting eating patterns and a rise of occupational 
and leisure activities that promote a primarily sedentary lifestyle – the burden of diabetes and 
dementia is poised to dramatically increase in the coming decades.4 According to the International 
Diabetes Federation (IDF) 2017 Atlas, global diabetes prevalence is projected to grow 48% to 629 
million by 2045.4 This translates to a steep financial costs to healthcare systems alongside the obvious 
human costs. The global economic burden of diabetes has been estimated at $1.3 trillion annually and 
is projected to surpass $2.5 trillion by 2030.5  
Prediabetes 
A major challenge in addressing the global burden of diabetes is a growing epidemic of prediabetes, a 
state of intermediate hyperglycemia situated between normal glycemia and diabetes.6 Prediabetes 
affects approximately 352 million people worldwide (7.3% of the global adult population) and this is 
expected to increase to 587 million people (8.3% of the global adult population) by 2045.4 Prediabetes 
is especially common in older adults, affecting 52% of European adults (and 53% of Swedish adults) 
aged ≥60 years, according to IDF.7  
Prediabetes is a high-risk state for developing overt diabetes.6 It has been estimated that between 5% 
and 10% of the prediabetes population progresses to diabetes annually and 70% of all prediabetes 
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cases ultimately will give rise to diabetes.6 Approximately 90% of prediabetes cases are undiagnosed, 
owing to heterogeneity in the diagnostic criteria for prediabetes, a lack of prediabetes screening 
efforts, and low awareness of prediabetes as a serious health condition.8,9  
However, in contrast to diabetes, prediabetes is not a chronic condition. Not everyone with 
prediabetes will progress to diabetes, and it is even possible to revert to normoglycemia. Indeed, a 
recent longitudinal study estimated that 22% of people with prediabetes could revert back to 
normoglycemia over more than a decade of follow up.10 This makes prediabetes an ideal window for 
interventions to prevent diabetes and its complications.  
Diabetes complications and comorbidities 
Chronic hyperglycemia has detrimental effects on many organ systems of the body. Accordingly, 
diabetes is associated with a wide range of adverse complications including cardiovascular disease, 
kidney disease, retinopathy, neuropathy, and low-extremity amputations, making it a leading cause of 
death and disability worldwide.1,4 The American Diabetes Association (ADA) recommends a glycated 
hemoglobin (HbA1c) target of <7% to prevent or delay the onset of these complications, particularly 
microvascular complications (i.e. kidney disease, retinopathy, and neuropathy).11 However, a less 
strict glycemic target of HbA1c <7.5% is considered more appropriate for older adults to minimize 
their risk of hypoglycemia (i.e. dangerously low blood sugar) and to reduce therapeutic complexity.12 
Furthermore, in patients with a shorter life expectancy, there are diminishing benefits to the strategy 
of using strict glycemic control to lower the risk of long-term diabetes complications.13  
Heart disease (e.g. myocardial infarction [MI], coronary artery disease, heart failure) is one of the 
major comorbidities of diabetes, and it is associated with increased mortality.14,15 It has been estimated 
that over half of people with diabetes (67% of men and 57% of women) will eventually develop heart 
disease,14 and as high as 80% could ultimately die from cardiovascular causes (vs. 30% of the 
diabetes-free population).15 The mechanisms behind the association between diabetes and heart 
disease are complex and multifactorial. The hyperglycemia that characterizes diabetes can damage 
blood vessels, contributing to the risk of ischemic stroke and MI.16 At the same time, people with 
diabetes are more likely to have existing risk factors for atherosclerotic heart disease, such as 
hypertension, high cholesterol, and obesity.17 
 
II. Dementia 
Diabetes affects also the brain.18 To this end, dementia and cognitive impairment are becoming 
increasingly recognized as potential complications of diabetes.   
Dementia is a highly heterogeneous syndrome characterized by progressive loss of cognitive 
functioning and physical independence. Cognitive dysfunction can manifest as memory loss, 
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challenges in planning and problem solving, confusion with time and place, problems with speaking 
or writing, impaired judgment and decision making, and behavioral symptoms such as changes in 
mood and personality.19 Beyond the cognitive symptoms, dementia  also involves loss of functional 
independence for instrumental activities of daily life (IADL; e.g. eating, bathing, dressing, personal 
hygiene, toilet hygiene, moving from one place to another).19 This translates to an enormous physical 
and psychological burden for patients, their families, and society – made worse by the current lack of 
disease-modifying therapy for dementia.20  
The majority (50% to 70%) of dementia cases are caused by Alzheimer’s disease, characterized by 
neuronal death and damage accompanied by abnormal accumulation of the protein beta-amyloid 
outside neurons and the protein tau inside neurons.19,21 The next most common cause of dementia is 
vascular dementia, which involves neuronal damage from infarcts or bleeding in the brain due to 
blood vessel blockage.19,21 Other neurodegenerative forms of dementia include dementia with Lewy 
bodies (DLB) and frontotemporal lobar degeneration (FTLD).19 Furthermore, it is increasingly 
recognized that neurodegenerative and vascular pathologies often co-occur in the aging brain, making 
mixed pathologies the most common cause of dementia.22,23  
Prevalence and cost of dementia 
An estimated 50 million people worldwide live with dementia, including approximately 10.5 million 
in Europe.19,24 Likewise, approximately 10 million new cases of dementia are diagnosed worldwide 
each year.25 Prevalence increases dramatically with age: in the European population, dementia 
prevalence starts at 2.6% for individuals aged 65-69 and rises to 4.3% for ages 70-74, 7.4% for ages 
75-79, 12.9% for ages 80-84, 21.7% for ages 85-89, and 43% for ages ≥90.26 As the global population 
ages, the World Health Organization (WHO) predicts that dementia prevalence is on pace to triple to 
150 million by 2050.25 In financial terms, dementia accounts for between $818 billion and $948 
billion in global spending per year, costs that are rising at an alarming rate of >20% year over year.21,27 
Per patient, dementia is the most costly disease facing society.21,28 
Cognitive impairment  
Dementia is characterized by a long preclinical and prodromal phase.29 Brain changes associated with 
dementia could occur 20 years or more before any clinical symptoms begin to manifest.19 Likewise, 
studies indicate that subtle, early impairments in various cognitive abilities (namely domains such as  
memory, attention, information processing speed, executive function, reasoning, visuospatial abilities, 
and language)21,30 can be detected nearly a decade before the clinical diagnosis of dementia.31,32  
Cognitive impairment represents an intermediate state between expected age-related cognitive 
changes and the appearance of dementia.33 Over the years, the concept of cognitive impairment has 
evolved and several terminologies and relative operationalizations have been proposed. Mild 
cognitive impairment (MCI) is the most common construct within this.33 While ongoing refinements 
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of the definition are still debated,33,34 in general MCI is agreed to involve the following: (i) absence of 
dementia; (ii) subjective cognitive complaint; (iii) objective impairment in one or more cognitive 
domains (memory, executive function/attention, language, or visuospatial skills); and (iv) essentially 
preserved independence in functional abilities (IADL).35 A similar but more broadly-defined 
formulation for cognitive impairment is cognitive impairment–no dementia (CIND), which describes 
a level of cognitive functioning that falls below normal, but does not meet the criteria for 
dementia.36,37 MCI is well-suited for making diagnoses in clinical practice since its criterion of 
subjective cognitive complaint is associated with increased risk of progression to Alzheimer’s 
dementia.38,39 For epidemiological purposes, CIND appears better suited as its strength lies in 
capturing a broader spectrum of cognitive impairment, including forms attributable to non-
degenerative causes (e.g. related to vascular or metabolic conditions).38  
Systematic reviews estimate that 16% to 20% of people ≥65 years have MCI globally,38 and between 
32% and 38% of MCI cases progress to dementia within five years.39,40 Though CIND has been less 
addressed, its estimated prevalence falls within a similar range: 25% in a study of Swedish twins (≥65 
years),41 16.8% in a Canadian population study (≥65 years),36 and 12.8% in a Portuguese population 
study (55-79 years).42 Reported progression rates from CIND to dementia have been estimated at 12% 
to 38% over one year,43,44 36% over two years,45 and 42% over five years.46   
While on one hand the high prevalence of cognitive impairment foreshadows a rise in dementia 
incidence, on the other hand emerging evidence suggests that up to 22% of people with cognitive 
impairment could eventually revert to nearly normal cognitive function.47,48 Therefore, similarly to 
prediabetes, cognitive impairment also represents a hopeful window for intervention and risk factor 
control to prevent the onset of overt dementia.  
Risk factors for dementia  
Advanced age is by far the dominant risk factor for cognitive impairment and dementia, followed by a 
positive family history of dementia and, for Alzheimer’s disease specifically, carrying one or more 
copies of the apolipoprotein ɛ4 (APOE ɛ4) allele.19 However, recent estimates suggest that over half 
of the burden of dementia worldwide could be attributable to seven potentially modifiable risk 
factors.49 These include diabetes, midlife hypertension, midlife obesity, physical inactivity, 
depression, smoking, and low educational attainment.49 Specifically, diabetes confers nearly double 
the risk of dementia,18,50 and it has been estimated that nearly 3% of all dementia cases are attributable 
to diabetes itself51 and as much as 10% are attributable to the spectrum of metabolic disturbances 
brought on by diabetes.18  
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III. Diabetes and Cognitive Impairment  
Despite the body of evidence associating diabetes with dementia, it is less clear whether there is a 
relationship between diabetes and cognitive impairment – cross-sectionally, longitudinally, and in 
terms of progression from cognitive impairment to dementia.  
Cross-sectional relationship 
In the past decade, eight studies have addressed the relationship between diabetes and cognitive 
impairment. The methods and findings of these studies are summarized in Appendix 1. Overall, five 
studies reported a positive association between diabetes and cognitive impairment,52–56  while two 
reported no association.57,58 The remaining study partitioned the analysis by age, finding an 
association between diabetes and cognitive impairment in middle age (50-65 years) but not old age 
(65-80 years).59 Altogether these findings suggest that diabetes is likely associated with cognitive 
impairment, but results are mixed.  
Discrepancies among these findings likely reflect methodological differences, particularly with regard 
to how diabetes and cognitive impairment were defined. While most studies thoroughly assessed 
diabetes based on a combination of self-report, medical records, and HbA1c or fasting plasma glucose 
(FPG) measurements, one relied solely on medical records53 and one explicitly excluded people with 
undiagnosed diabetes.59  Furthermore, the majority of the studies measured cognitive impairment in 
terms of MCI,53,55,57–60 but some instead used CIND56 or raw cognitive test score cut-offs.52 There were 
also substantial differences in the ages of the various study populations (ranging from ≥40 years to 
≥70 years), as well as which covariates (e.g. age, sex, race, education, APOE ɛ4 genotype) were 
accounted for in the analyses.  
Longitudinal relationship 
Nine studies have addressed the longitudinal relationship between diabetes and cognitive impairment 
over the past 15 years.60–68 The methods and findings of these studies are summarized in Appendix 2. 
A substantial amount of disagreement surrounds this question. To date five studies have reported a 
positive association between diabetes and cognitive impairment over time,60–63,66 while four reported 
no association.64,65,67,68 All studies evaluated cognitive impairment in terms of MCI. 
There are several methodological discrepancies between these studies. Most importantly, the duration 
of follow-up ranged widely, from just 3 years62 to 7.6 years65 (the majority of studies fell somewhere 
between 4 and 5 years).60,61,63,64,67 As for diabetes diagnosis, most studies used a combination of self-
report, medical records, and laboratory tests, but the cutoff values for these tests were slightly variable 
(e.g. ≥6.0% vs. ≥6.5% HbA1c and ≥7.0 mmol/L vs. ≥7.8 mmol/L for FPG). Additionally, the ages of 
the study populations represented here were quite variable (ranging from ≥55 years62 to ≥75 years64), 
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as were the covariates accounted for in the analysis (e.g. age, sex, race, education, APOE ɛ4 
genotype). 
Progression to dementia  
Over the past 15 years, ten studies have addressed the relationship between diabetes and the 
progression from cognitive impairment to dementia over time.61,64,69–76 The methods and findings of 
these studies are summarized in Appendix 3. Five studies have reported a positive association 
between diabetes and the progression from cognitive impairment to dementia,64,70,72–74 while five 
reported no association.61,69,71,75,76 Again, all studies evaluated cognitive impairment in terms of MCI.  
Methodological discrepancies that may explain these inconsistent findings again include duration of 
follow-up (from 1 year71 to 5 years61,69,73), diabetes diagnosis (several studies62,69,73,74,76 relied on self-
report and medication use alone without biomarker testing), and biomarker thresholds for defining 
diabetes (HbA1c vs. FPG, and within FPG ≥7.0 mmol/L vs. ≥7.8 mmol/L). There were additionally 
major differences in the demographics of the study populations and the covariates accounted for in the 
analyses (e.g. age, sex, race, education, APOE ɛ4 genotype). 
 
IV. Prediabetes and Cognitive Impairment 
In contrast to the literature on diabetes and cognitive impairment, very few studies have addressed 
prediabetes in relation to cognitive impairment and progression to dementia.  
Cross-sectional relationship 
No study to date has directly assessed the cross-sectional association between prediabetes and 
cognitive impairment. The investigation that most closely approaches this question is a 2017 Japanese 
population study of people ≥70 years of age.77 The study was primarily concerned with the association 
between metabolic syndrome and MCI, but included sub-analyses for the individual components of 
metabolic syndrome, one of which is impaired glucose tolerance (IGT, e.g. either prediabetes or 
diabetes). IGT was positively associated with non-amnestic forms of MCI in both men and women 
(OR: 1.62, 95% CI: 1.19-2.22; OR: 1.32, 95% CI: 1.02-1.71), but not with MCI involving memory 
loss.77 Furthermore, a small 2019 cohort study across several western European countries also 
examined IGT as sub-analyses of the various components of metabolic syndrome.78 The study found 
no association between IGT and either MCI or CIND, though it is worth noting that the 
generalizability of this study is limited given its small size (n=202) and the fact that the study 
population encompassed only people undergoing elective surgery.  
Longitudinal relationship 
Of two longitudinal studies to examine the relationship between prediabetes and the development of 
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cognitive impairment – a 2010 Swedish population study (Xu et al. 2010)64 and a 2004 population 
study across the United States and Canada (Yaffe et al. 2004)67 – both found no association.  
Progression to dementia  
To our knowledge, Xu et al. 2010 is the only study to date that has investigated the longitudinal 
relationship between prediabetes and progression from cognitive impairment to dementia. Using 
Swedish population data from the Kungsholmen Project, the study found a strong association between 
prediabetes and the development of both dementia (HR=5.0, 95% CI: 2.3-10.1) and Alzheimer’s 
disease (HR=5.7, 95% CI: 2.4-13.5) in people with baseline MCI.64 Prediabetes was defined as 
random blood glucose level of 7.8-11.0 mmol/L in diabetes-free participants, in contrast to more 
commonly-used HbA1c or FPG thresholds. More studies are needed to conclusively determine 
whether this relationship between prediabetes and progression to dementia holds in other populations 
and with other prediabetes diagnoses.  
 
V. Mechanisms  
The mechanisms underpinning the association between diabetes and cognitive impairment have not 
yet been clearly delineated. Two non-mutually-exclusive candidate mechanisms include 
hyperglycemia and inflammation.  
The chronic hyperglycemia that characterizes diabetes can lead to progressive structural and 
functional abnormalities in the brain. Evidence suggests that the toxic effects of hyperglycemia are 
mediated through many pathways, including disturbances of intracellular second messenger pathways, 
increased formation of advanced glycation end products (AGEs), increased glucose shunting through 
the polyol and hexosamine pathways, overproduction of reactive oxygen species, and altered 
glycation of proteins.79 This can have damaging effects on the brain via (i) direct degradation of the 
myelin sheath, leading to signal processing dysfunction and neuron death, or (ii) by inducing 
microvascular and macrovascular changes that impair neural function indirectly.79,80  In this way, 
hyperglycemia is thought contribute to widespread “micro-infarcts” in the brain that can lead to brain 
atrophy over time. In turn, this may lead to cognitive impairment and dementia, or lower the threshold 
for these to occur in response to other insults.79  
The systemic inflammation that is associated with diabetes may also contribute to cognitive 
impairment and dementia.81 In animal studies overproduction of inflammatory cytokines is associated 
with neurodegeneration, while in humans inflammatory markers are elevated in the brains of people 
with Alzheimer’s disease.81 Furthermore, epidemiological studies point to an association between 
inflammatory markers like C-reactive protein (CRP), interleukin-6 (IL-6), and fibrinogen and elevated 
risk of cognitive decline and dementia.81 Turning to pathophysiology, there are several pathways 
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through which the peripheral inflammatory mediators that characterize diabetes could reach the brain, 
including activation of cerebral endothelial cells or direct transport across the blood-brain-barrier.81  
 
VI. Knowledge Gaps  
Within this body of literature, several knowledge gaps remain:  
First, the relationship between diabetes and cognitive impairment is not well-understood, especially in 
the context of CIND. Previous observational studies investigating the cross-sectional and longitudinal 
associations between diabetes and cognitive impairment have primarily focused on MCI (Appendices 
1-3) and not CIND, which is more suitable for observational studies.38 
Additionally, prediabetes has been insufficiently explored. No previous studies have investigated the 
cross-sectional association between prediabetes and cognitive impairment, and uncertainty remains 
regarding whether prediabetes impacts the incidence of cognitive impairment or its progression to 
dementia.  
Furthermore, it is unclear whether (pre)diabetes acts alone to impact risk of cognitive impairment and 
dementia, or within a cluster of wider vascular disorders. Given the strong overlap between diabetes 
and other cardiovascular conditions and the symbiotic relationship between the brain and the heart, it 
is plausible that additional vascular diseases (i.e. heart disease) could exacerbate the effect of diabetes 
on cognitive aging.  
Finally, the mechanisms underlying the impact of diabetes on cognitive impairment are poorly 
understood, although evidence points to diabetes-associated hyperglycemia and inflammation as two 
possible candidates.  
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R e s e a r c h  H y p o t h e s i s  
This thesis tests the hypothesis that (pre)diabetes adversely impacts cognitive function, increasing the 
risk of CIND and its progression to dementia over time. Vascular conditions, such as heart disease, 
could exacerbate diabetes’ impact on cognitive impairment. Furthermore, the mechanisms by which 
diabetes impacts cognitive function could relate to hyperglycemia and inflammation.  
 
 
Figure 1. Schematic representation of the research hypothesis 
 
S t u d y  A i m s  
The overall aim of this thesis is to investigate the impact of prediabetes and diabetes on cognitive 
impairment, exploring factors that exacerbate this relationship and possible underlying mechanisms.   
Specifically, the following three aims were addressed: 
• To investigate the associations between prediabetes, diabetes, and the development of CIND; 
• To examine the extent to which prediabetes and diabetes accelerate the progression of CIND 
to dementia;  
• To assess the role of heart disease, hyperglycemia, and inflammation in the associations 
between (pre)diabetes and CIND and its progression to dementia.  
 10 
M e t h o d s  
This study is based on baseline and 3-, 6-, 9-, and 12-year follow-up data from the ongoing 
population-based Swedish National Study on Aging and Care-Kungsholmen (SNAC-K).82  
 
Study population  
The SNAC-K population is comprised of a random sample of individuals aged ≥60 years living at 
home or in institutions in the Kungsholmen district, in central Stockholm, Sweden. Of 5,111 people 
initially invited to the study, 4,790 were alive and eligible at baseline and 3,363 (73.3%) agreed to 
participate in the baseline survey (March 2001 through June 2004). The sampling was stratified by 
eleven age-specific cohorts (60, 66, 72, 78, 81, 84, 87, 90, 93, 96, and ≥99 years) and participants are 
followed every third or sixth year (Figure 2). Because older age groups tend to experience more rapid 
changes in health and a higher study attrition rate, cohorts with individuals 78 years of age or older 
are followed up every three years, whereas cohorts with participants below 78 years of age are 
followed up every six years (until they reached the age of 78 at which point three year follow-ups 
were instituted). In this thesis, data were available up to 2016, for a maximum of 15 years follow-up 
period. 
 
 
Figure 2. The Swedish National Study on Aging and Care – Kungsholmen (SNAC-K) study 
design. Pictured are the waves of SNAC-K assessment included in this analysis, from baseline (B) to 
the most recent follow-up for which data were available (F1=first, F2=second, F3=third, and F4=fourth 
follow-up). Modified from https://snack.se/about/study-plan  
 11 
 
Because the present project focuses on the prodromal phase of dementia associated with prediabetes 
and type 2 diabetes, participants with dementia at baseline (n=250), missing data on baseline CIND 
status (n=464) or baseline HbA1c (n=67), neuro-psychiatric conditions (n=39 with Parkinson’s 
disease, schizophrenia, or developmental disorders), and type 1 diabetes (n=20) were excluded. 
Furthermore, we also excluded individuals living in nursing homes (n=14) to avoid any possible 
misclassification of the outcome due to frailty and lack of functional independence. We additionally 
excluded one individual with prediabetes who was taking diabetes medication. Thus, this project 
included a total of 2,508 participants (Figure 3).  
Based on cognitive function at baseline, the 2,508 participants were divided into to a cognitively-
intact cohort (n=1,837) and a CIND cohort (n=671). The two cohorts were followed until 2016, 
during which incident CIND and dementia cases were detected. 
 
Figure 3. Flowchart of SNAC-K study population.  
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Ethical approval  
SNAC-K was approved by the Ethical Committee at Karolinska Institutet and the Regional Ethical 
Review Board in Stockholm, Sweden, including linkage with registries. Written informed consent 
was obtained from all participants, or from a proxy (i.e. family member or guardian) in the case of 
cognitive impairment.  
 
Data collection 
Following the standard SNAC-K protocol (available at https://www.snac-k.se/about/study-plan/), 
participants underwent the following examinations at baseline and during all follow-ups:  
• An interview with a nurse assessing demographic data (i.e. age, sex), education and 
occupational history, current and past socio-economic status, living arrangement, lifestyle 
habits (i.e. smoking, alcohol consumption), physical functioning (i.e. ability to manage 
activities of daily living, motility and strength, sensory functions), and history of care 
received in medical and social facilities. 
•  A self-administered form assessing the details of the individual’s social network, past and 
present leisure activities, nutritional habits, health-related quality of life (Short Form 12 
Health Survey), life satisfaction (Neugarten Life Satisfaction Index), well-being (PANAS), 
and self-perceived health (Ware’s Health Perceptions Questionnaire).  
• A clinical examination by physicians encompassing past clinical history, family history, 
geriatric and neurological examinations;  
• A neuropsychological assessment, in which standardized cognitive tests were administered 
by a trained psychologist to assess cognitive function;  
• Peripheral blood sample were collected from each participant for standard laboratory tests to 
evaluate biochemical markers.  
 
Assessment of diabetes and prediabetes  
HbA1c was measured from peripheral blood samples with Swedish Mono S filament high-
performance liquid chromatography, and 1.1% was added to the measured HbA1c values to equate 
them with international standards.83 
Diabetes was identified at baseline by combining information from multiple sources: medical 
examination, use of anti-hyperglycemic drugs, diagnoses from the Swedish National Patient Register 
and the Swedish Cause of Death Registry, or HbA1c measurements ≥6.5%. In diabetes-free 
participants, prediabetes was defined as HbA1c of ≥5.7% to 6.4%.84  
 13 
Participants with diabetes were classified as well-controlled (HbA1c <7.5%) or poorly-controlled 
(HbA1c ≥7.5%) according to recommended glycemic targets for older adults.12 
 
Assessment of cognitive impairment and dementia  
At baseline and at each wave of follow-up, CIND was defined as the presence of objective cognitive 
impairment in any domain, absent overt dementia.36  
The neuropsychological assessment included a battery of 10 cognitive tests addressing five major 
cognitive domains: episodic memory (free recall),85 perceptual speed (digit cancellation, pattern 
comparison),86,87 executive function (Trial Making Test B-number of correct items),30 visuospatial 
abilities (mental rotation task),30 and verbal fluency (category and letter fluency).30 At each wave of 
assessment, raw scores from the individual cognitive tests were standardized into Z-scores, using 
baseline means and standard deviations (SDs). The five cognitive domains were created using 
individual test Z-scores or by averaging the Z-scores of multiple tests. The division was made a priori, 
according to the standard neuropsychological practice and cognitive theory.30 
Cognitive Impairment-no dementia (CIND) was identified as having no dementia and a score ≤1.5 
SDs below age group-specific means on at least one cognitive domain of standardized cognitive 
tests.36 Dementia was defined according to the Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition (DSM-IV) revised criteria through a validated three-step procedure. Two examining 
physicians independently made preliminary diagnoses of dementia based on the participant’s physical, 
neurological, and cognitive status (steps 1 and 2). In the case of discrepancy between the two 
diagnoses, a senior neurologist was consulted to reach a final diagnosis (step 3).88 For participants 
who died during follow-up, the diagnosis of dementia was extracted from medical records or the death 
certificate, if available.  
 
Assessment of covariates 
Educational attainment was categorized into elementary, high school, and university, based on self-
report. Information on physical activity was based on the participants’ self-reported exercise habits 
and dichotomized as inactive and active (including moderate and vigorous exercise).88 Body mass 
index (BMI) was calculated as the ratio of weight to squared height (kg/m2) and grouped into the 
standard clinical categories: underweight (<20), normal weight (≥20-25), overweight (≥25-30), and 
obese (≥30). Smoking status was dichotomized as nonsmoking (participants who had never smoked) 
and current/ever smoking (including former and current smokers). Alcohol consumption was 
dichotomized as non-drinking (including non-drinkers and those who drink only occasionally) and 
drinking (including light-to-moderate and heavy drinkers).  
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Chronic medical conditions were ascertained based on physicians’ examination, medical history, 
medication use, lab tests, and linkage with the Swedish National Patient Register (NPR), which 
covers inpatient care from 1987 and outpatient care since 2001.89 Codes from the International 
Classification of Disease, tenth revision (ICD-10) were used to identify medical conditions including 
cerebrovascular diseases. Depression was diagnosed according to DSM-IV revised criteria.90 Arterial 
blood pressure was measured twice at a five minute interval on the left arm in a sitting position; 
hypertension was identified if blood pressure exceeded 140/90 mmHg. APOE allelic status was 
assessed using a microsequencing method (AffiGen APOE, Sangtec Medical) based on a polymerase 
chain reaction with biotinylated primers. The APOE genotype was dichotomized into carriers of at 
least one ε4 allele versus non-carriers.  
As for major covariates, heart diseases (atrial fibrillation, bradycardia, cardiac valve dysfunction, 
heart failure, ischemia, and peripheral vascular disease) were identified using ICD-10 codes. CRP was 
measured using a turbidimetric method (DXC800, Beckman Coulter). CRP was divided into three 
levels based on its distribution: normal (0-5 mg/L, lab reference value), high (6-20 mg/L), and very 
high (>20 mg/L). 
 
Statistical analyses  
Baseline characteristics of the study participants by cognitive status (cognitively-intact and CIND) 
and diabetes status (diabetes-free, prediabetes, and diabetes) were assessed using chi-square (χ2) tests 
or one-way ANOVA, followed by pairwise mean comparisons with Bonferroni correction.  
Multivariable logistic regressions were used to estimate the Odds Ratios (ORs) with 95% confidence 
intervals (CI) of having baseline CIND according to diabetes status.  
We assessed two longitudinal outcomes in separate analyses: the development of CIND (in the cohort 
that was cognitively-intact at baseline) and the progression to dementia (in the cohort that had CIND 
at baseline).   
In the cognitively-intact cohort, incidence rates (IRs) and 95% CIs of CIND per 1,000 person-years 
(in people with diabetes, prediabetes, and who were diabetes-free) were calculated as the number of 
events during the follow-up period divided by person-years of follow-up. Cox proportional hazards 
regression models were used to estimate the hazard ratios (HRs) and 95% CIs of developing CIND for 
participants with baseline diabetes or prediabetes, in comparison to those who were diabetes-free. 
Follow-up time was calculated as the time from study entry until CIND diagnosis, death, or last 
examination. The proportional hazard assumption was tested for all predictors and covariates in the 
model, using the Schoenfeld residuals regressed against follow-up time. Violations of proportionality 
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were observed for age (p<0.001) and heart disease (p=0.005), so the model was modified to stratify 
by these factors.  
The same procedure for calculating IRs and HRs was repeated for the CIND cohort, this time using 
dementia as the outcome. Follow-up time was calculated as the time from study entry until dementia 
diagnosis, death, or last examination. In testing the proportional hazard assumption for the Cox 
proportional hazards regression model, no violations of proportionality were observed. 
Because cardiovascular disease is a common comorbidity of diabetes and a risk factor for cognitive 
impairment and dementia,14,15 interactions between diabetes status and heart diseases were tested 
separately in the two cohorts (cognitively intact and CIND). First, we incorporated the two disorders 
(diabetes and heart disease) and their cross-product term in the same Cox regression model 
(multiplicative interaction). Next, we estimated the relative excess risk due to interaction (RERI) for 
the joint effect of diabetes and heart disease (additive interaction). Finally, to assess the joint 
association of diabetes and heart disease (effect modification) to predict CIND or the progression to 
dementia, we created an indicator variable that combined diabetes status (no vs. yes) with heart 
disease status (no vs. yes), effectively dividing the participants into four groups: (i) those who were 
diabetes-free and heart disease-free (“no disease”); (ii) those who had diabetes but no heart disease 
(“diabetes only”); (iii) those who had heart disease but no diabetes (“heart disease only”); and (iv) 
those who had both diabetes and heart disease (“diabetes and heart disease”). 
We additionally tested interactions between diabetes status and CRP levels in the two cohorts, given 
the role of systemic inflammation in the pathogenesis of both diabetes and cognitive aging.81 We 
incorporated the diabetes, elevated (i.e. “high” or “very high”) CRP levels, and their cross-product 
term in the same Cox regression model (multiplicative interaction). Furthermore, we estimated the 
RERI for the joint effect of CRP levels and combined diabetes and heart disease status (additive 
interaction).   
To examine the role of hyperglycemia in relation to CIND and progression to dementia, separate 
logistic and Cox regression models were repeated according to the glycemic status (diabetes-free 
[reference], well-controlled diabetes, and poorly-controlled diabetes). 
Age, sex, education, physical activity, BMI, heart disease, cerebrovascular disease, hypertension, and 
APOE ɛ4 status were considered as possible confounders and accounted for in data analysis.  
All reported P values were two-sided, and P values <0.05 were considered statistically significant. All 
statistical analyses were performed using Stata SE 15.0 (StataCorp LP, College Station, Texas, USA). 
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R e s u l t s  
Baseline characteristics of the two study cohorts  
Overall, of the 2,508 participants at baseline, 1,837 (73%) were cognitively-intact, 671 (27%) had 
CIND, 217 (9%) had diabetes, and 853 (34%) had prediabetes. 
Tables 1 and 2 show the baseline characteristics in the cognitively-intact and CIND cohorts by 
diabetes status. In the cognitively-intact cohort, 133 (7%) participants had diabetes and 615 (34%) had 
prediabetes. Participants with diabetes or prediabetes were more likely to be older, to have lower 
levels of education, to currently drink less alcohol, and be less physically active than participants 
without diabetes. Moreover, they were more likely to have overweight or obesity, hypertension, heart 
disease, and elevated CRP levels (Table 1). In the CIND cohort, 84 (13%) participants had diabetes 
and 238 (36%) had prediabetes. Participants with diabetes were more likely to be older, to have higher 
BMI, more heart diseases and elevated CRP levels (Table 2).  
We additionally compared the two cohorts (Table 3). Overall, the cognitively-intact cohort had a 
better health than the CIND cohort at baseline. In addition, among participants with diabetes, 31 
(23%) in the cognitively-intact cohort and 28 (33%) in the CIND cohort had poor glycemic control. 
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Table 1. Baseline characteristics of the cognitively-intact cohort by diabetes status (n=1,837) 
Characteristics Diabetes-Free  n=1,089  
Prediabetes 
 n=615 
 Diabetes 
n=133 
 p 
Age, years 69.8 ± 9.1  72.9 ± 9.7*  72.4 ± 9.2*   <0.001 
60 to <72 614 (56.4)  261 (42.4)  54 (40.6)  
<0.001 
72 to <81 300 (27.6)  201 (32.7)  50 (37.6)  
81 to <90 142 (13.0)  121 (19.7)  24 (18.1)  
90+ 33 (3.0)  32 (5.2)  5 (3.8)  
Female  656 (60.2)  388 (63.1)  57 (42.9)  <0.001 
Education        
Elementary 93 (8.5)  81 (13.2)  18 (13.5)  
0.001 High school 503 (46.2)  295 (48.0)  72 (54.1)  
University 493 (45.3)  239 (38.9)  43 (32.3)  
Current/ever smokers 595 (54.8)  350 (57.2)  74 (56.5)  0.635 
Current alcohol drinkers 867 (79.8)  425 (69.1)  89 (67.4)  <0.001 
Physically active 888 (81.5)  459 (74.6)  88 (66.2)  <0.001 
BMI, kg/m2  25.5 ± 3.7  26.2 ± 4.1*  27.8 ± 3.8*  <0.001 
Underweight (<20) 48 (4.4)  24 (3.9)  -  
<0.001 
Normal (20–25) 480 (44.1)  228 (37.1)  34 (25.6)  
Overweight (25–30) 450 (41.3)  263 (42.8)  59 (44.4)  
Obese (≥30) 111 (10.2)  100 (16.3)  40 (30.1)  
HbA1c, % 5.3 ± 0.22  5.9 ± 0.18*  7.1 ± 1.3*  <0.001 
Heart disease  172 (15.8)  142 (23.1)  51 (38.4)  <0.001 
Cerebrovascular diseases 43 (4.0)  38 (6.2)  7 (5.3)  0.113 
Hypertension 730 (67.0)  417 (67.8)  111 (83.5)  0.001 
Depression 38 (3.5)  22 (3.6)  4 (3.0)  0.947 
CRP, mg/L 5.8 ± 3.8  6.5 ± 6.3*  6.7 ± 5.5  0.008 
     Normal (0-5) 909 (83.5)  488 (79.4)  95 (71.4)  
0.006      High (6-20) 153 (14.1)  103 (16.8)  31 (23.3)  
     Very high (>20) 27 (2.5)  24 (3.9)  7 (5.3)  
APOE ɛ4  310 (29.5)  169 (28.8)  31 (24.4)  0.486 
Data are presented as means ± standard deviations or number (proportion %). 
Missing data: Smoking=9, Alcohol=3, HbA1c=2, Depression=4, CRP=28, APOE ɛ4=74  
*Pairwise means comparison using the Bonferroni correction: p<0.05 (reference group=baseline 
participants who were cognitively intact) 
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Table 2. Baseline characteristics of the CIND cohort by diabetes status (n=671) 
Characteristics Diabetes-Free  n=349  
Prediabetes 
 n=238 
 Diabetes 
n=84 
 p 
Age, years 74.3 ± 10.4  77.5 ± 10.6 *  75.6 ± 9.1   0.002 
60 to <72 128 (36.7)  58 (24.4)  22 (26.2)  
0.013 
72 to <81 116 (33.2)  79 (33.2)  35 (41.7)  
81 to <90 58 (16.6)  55 (23.1)  17 (20.2)  
90+ 47 (13.5)  46 (19.3)  10 (11.9)  
Female  236 (67.6)  174 (73.1)  39 (46.4)  <0.001 
Education        
Elementary 74 (21.2)  62 (26.1)  23 (27.4)  
0.240 High school 188 (53.9)  132 (55.5)  40 (47.6)  
University 87 (24.9)  44 (18.5)  21 (25.0)  
Current/ever smokers 171 (49.4)  129 (54.4)  50 (60.2)  0.160 
Current alcohol drinkers 206 (59.4)  117 (49.6)  37 (44.6)  0.012 
Physically active 230 (65.9)  151 (63.5)  49 (58.3)  0.417 
BMI, kg/m2  24.9 ± 3.8  25.5 ± 4.1  27.3 ± 5.5*  <0.001 
Underweight (<20) 25 (7.2)  17 (7.1)  7 (8.3)  
<0.001 
Normal (20–25) 174 (49.9)  107 (45.0)  23 (27.4)  
Overweight (25–30) 121 (34.7)  83 (34.9)  31 (36.9)  
Obese (≥30) 29 (8.3)  31 (13.0)  23 (27.4)  
HbA1c, % 5.3 ± 0.24  5.9 ± 0.20*  7.2 ± 1.4*  <0.001 
Heart disease  85 (24.4)  91 (38.3)  49 (58.3)  <0.001 
Cerebrovascular diseases 27 (7.7)  22 (9.2)  10 (11.9)  0.458 
Hypertension 253 (72.5)  186 (78.2)  59 (70.2)  0.206 
Depression 28 (8.1)  15 (6.3)  8 (9.6)  0.556 
CRP, mg/L 6.8 ± 9.1  6.1 ± 3.4  7.2 ± 5.1  0.356 
    Normal (0-5) 278 (79.7)  178 (74.8)  54 (64.3)  
0.005      High (6-20) 55 (15.8)  54 (22.7)  22 (26.2)  
     Very high (>20) 16 (4.6)  6 (2.5)  8 (9.5)  
APOE ɛ4  100 (31.6)  68 (30.2)  18 (23.1)  0.342 
Data are presented as means ± standard deviations or number (proportion %). 
Missing data: Smoking=5, Alcohol=5, HbA1c=3, Depression=4, CRP=17, APOE ɛ4=51  
*Pairwise means comparison using the Bonferroni correction: p<0.05 (reference group=baseline 
participants who were cognitively intact) 
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Table 3. Baseline characteristics of cognitively-intact and CIND cohorts (n=2,508) 
Characteristics Intact  n=1,837  
CIND 
 n=671 
 p 
Age, years 71.0 ± 9.5  75.6 ± 10.4 *  <0.001 
60 to <72 929 (50.6)  208 (31.0)  
<0.001 
72 to <81 551 (30.0)  230 (34.3)  
81 to <90 287 (15.6)  130 (19.4)  
90+ 70 (3.8)  103 (15.4)  
Female  1101 (59.9)  449 (66.9)  0.001 
Education      
Elementary 192 (10.5)  159 (23.7)  
<0.001 High school 870 (47.4)  360 (53.7)  
University 775 (42.2)  152 (22.7)  
Current/ever smokers 1019 (55.7)  350 (52.6)  0.156 
Current alcohol drinkers 1381 (75.3)  360 (54.1)  <0.001 
Physically active 1435 (78.1)  430 (64.1)  <0.001 
BMI, kg/m2  25.9 ± 3.9  25.4 ± 4.2*  0.01 
Underweight (<20) 72 (3.9)  49 (7.3)  
<0.001 
Normal (20–25) 742 (40.4)  304 (45.3)  
Overweight (25–30) 772 (42.0)  235 (35.0)  
Obese (≥30) 251 (13.7)  83 (12.4)  
HbA1c, % 5.6 ± 0.63  5.8 ± 0.80*  <0.001 
Diabetes status      
Diabetes-free 1089 (59.3)  349 (52.0)  
<0.001 Prediabetes 615 (33.5)  238 (35.5)  
Diabetes 133 (7.2)  84 (12.5)  
     Well-controlled (HbA1c <7.5%) 102 (76.7)  56 (66.7)  
<0.001      Poorly-controlled (HbA1c ≥7.5%) 31 (23.3)  28 (33.3)  
Heart disease  365 (19.9)  225 (33.5)  <0.001 
Cerebrovascular diseases 88 (4.8)  59 (8.8)  <0.001 
Hypertension 1258 (68.5)  498 (74.2)  0.006 
Depression 64 (3.5)  51 (7.7)  <0.001 
CRP, mg/L 6.1 ± 4.9  6.6 ± 7.1  0.065 
     Normal (0-5) 1492 (81.2)  510 (76.0)  
0.014      High (6-20) 287 (15.6)  131 (19.5)  
     Very high (>20) 58 (3.2)  30 (4.5)  
APOE ɛ4  510 (28.9)  186 (30.0)  0.614 
Data are presented as means ± standard deviations or number (proportion %). 
Missing data: Smoking=14, Alcohol=8, HbA1c=5, Depression=8, CRP=45, APOE ɛ4=125 
*Pairwise means comparison using the Bonferroni correction: p<0.05 (reference group=baseline 
participants who were cognitively intact) 
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Cross-sectional associations between (pre)diabetes and cognitive impairment  
Multi-adjusted logistic regression models showed that individuals with diabetes were 72% more likely 
to have CIND at baseline compared to those who are diabetes-free (OR=1.72, 95% CI: 1.23-2.41) 
(Figure 4). This relationship was stronger for poorly-controlled diabetes (HbA1c ≥7.5%), which was 
associated with three-times greater likelihood of CIND (OR=2.7, 95% CI: 1.45-4.93).  
Such an association was not observed for prediabetes (OR=1.07, 95% CI: 0.86-1.32).  
 
Figure 4. Logistic regressions’ odds ratios (ORs) reflecting the probability of baseline CIND by 
diabetes status. Model adjusted for baseline age, sex, education, physical activity, BMI class, heart 
disease, cerebrovascular disease, hypertension, and APOE ε4.  
 
Diabetes status, incident CIND, and progression to dementia 
During follow-up (mean 9.2 ± 3.0 years [range=2.2-15.5 years]), 544 (30%) individuals in the 
cognitively-intact cohort developed CIND. In the CIND cohort, 132 (20%) individuals progressed to 
dementia during follow-up (mean 7.7 ± 4.0 years [range=0.2-15.2 years]). Table 4 describes the 
incident rates of CIND and dementia in the cognitively-intact and CIND cohorts, respectively. For 
both development of CIND and progression to dementia, incidence rates were highest for participants 
with diabetes, particularly if they had poor glycemic control (HbA1c ≥7.5%) (Table 4). 
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Table 4. Incidence rates (IR) per 1000 person-years with 95% CI of CIND and dementia by diabetes 
and glycemic status. 
 
 
A multi-adjusted Cox proportional hazards model showed that diabetes was borderline associated 
with increased risk of CIND (HR 1.4, 95% CI:0.98-1.88, p=0.068) in the cognitively intact cohort 
(Table 5). This was primarily driven by participants with poorly-controlled diabetes (HbA1c ≥7.5%) 
who showed 2-times higher risk of developing CIND than those who were diabetes-free (HR 2.0, 
95% CI:1.11-3.48). Furthermore, in the CIND cohort, poorly-controlled diabetes was also associated 
with a 3-times higher risk of dementia progression (HR 3.3, 95% CI: 1.29-8.33).  
No associations between prediabetes and CIND were detected in either cohort (Table 5).  
 
 
Incident CIND Progression from CIND to 
Dementia 
No. events/ 
person-year IR (95% CI)  
No. events/ 
person-year 
IR (95% CI) 
Diabetes-free 307 / 8,691 35.3 (31.6–39.5)  70 / 2,724 25.7 (20.3–32.5) 
Prediabetes 191 / 4,397 43.4 (37.7–50.1)  43 / 1,691 25.4 (18.7–34.3) 
Diabetes  46 / 873 52.7 (39.5–70.3)  19 / 517 36.7 (23.4–57.6) 
HbA1c <7.5%  32 / 652 49.1 (34.7–69.4)  11 / 381 28.8 (16.0–52.1) 
HbA1c ≥7.5% 14 / 221 63.3 (37.5–106.9)  8 / 136 59.0 (29.5–117.9) 
Total  544 / 13,961 39.0 (35.8–42.4)  132 / 4,932 26.8 (22.6–31.7) 
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Table 5. Hazard ratios (HR) with 95% CI of incident CIND and progression to dementia by diabetes and glycemic status. 
 
Incident CIND  Progression from CIND to Dementia 
 Basic-adjusted  Multi-adjusted   Basic-adjusted Multi-adjusted 
n HR (95% CI) * HR (95% CI) †  n HR (95% CI) * HR (95% CI) † 
Diabetes-free 1,089 Reference Reference  349 Reference Reference 
Prediabetes 615 1.1 (0.96–1.38) 1.1 (0.94–1.36)  238 0.81 (0.55–1.18) 0.78 (0.52–1.17) 
Diabetes 133 1.4 (0.99–1.86) ǂ 1.4 (0.98–1.88) ǂ  84 1.4 (0.82–2.31) 1.2 (0.68–2.07) 
     HbA1c <7.5% 78 1.2 (0.86–1.79) 1.2 (0.86–1.79)  43 1.0 (0.54–1.94) 0.87 (0.44–1.69) 
     HbA1c ≥7.5% 55 1.7 (1.00–2.94) ǂ 2.0 (1.11–3.48)   41 2.8 (1.28–5.91) 3.3 (1.29–8.33)  
* Basic-adjusted for baseline age, sex, and education. 
† Multi-adjusted for baseline age, sex, education, vascular risk factors (i.e. physical activity and BMI), heart disease, cerebrovascular disease, hypertension, 
and APOE ԑ4.  
ǂ p-value <0.07 indicating borderline statistical significance. 
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The role of cardiovascular diseases  
We tested whether diabetes and poorly-controlled diabetes interacted synergistically with 
cardiovascular diseases in exacerbating the development of CIND and its progression to dementia. 
In the cognitively-intact cohort, there was no indication of a multiplicative interaction between 
diabetes and heart disease (p=0.145). Additionally, there was no additive interaction (RERI=0.19, 
95% CI: -0.33-0.70, p=0.497). Next, we further examined the joint association of diabetes and heart 
diseases in predicting cognitive impairment combining diabetes (no vs. yes) and heart disease (no vs. 
yes) in an indicator variable (Figure 5). Neither diabetes nor heart disease alone were associated with 
an increased risk of CIND. However, comorbid diabetes and heart disease were associated with more 
than double the risk of CIND (HR 2.2, 95% CI: 1.39-3.48, p=0.001) compared to disease-free 
participants. Poor glycemic control strengthened this association slightly (HR for the joint association 
between poorly-controlled diabetes [HbA1c≥7.5%] and heart disease = 2.3, 95% CI:1.09-4.64).  
 
Figure 5. Hazard ratios (HRs) with 95% CI of CIND for cognitively-intact participants by 
diabetes and heart disease status. Model adjusted for baseline age, sex, education, physical 
activity, BMI class, cerebrovascular disease, hypertension, and APOE ε4.  
 
In the CIND cohort, we found a statistically significant multiplicative interaction between diabetes 
and heart disease (p=0.040). Specifically, in participants with CIND and heart disease, the additional 
diagnosis of diabetes increased the risk of progressing to dementia by 2.5-fold (HR 2.5, 95% CI: 1.17-
5.47). This risk rises to nearly 6-fold when diabetes is poorly-controlled (HR 5.8, 95% CI: 1.72-19.3) 
(Table 6). 
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Table 6. Hazard ratios (HR) with 95% CI of progression to dementia for CIND cohort participants with 
and without heart disease, by diabetes status. 
 
 
 
 
 
 
 
 
 
 
† Multi-adjusted for baseline age, sex, education, vascular risk factors (i.e. physical activity and BMI), 
cerebrovascular disease, hypertension, and APOE ԑ4.  
 
The role of inflammation  
To assess the role of systemic inflammation in predicting diabetes-related cognitive impairment, we 
further tested interactions (multiplicative and additive) between diabetes or glycemic control and CRP 
levels. Because of the low number of participants with very high CRP levels in the prediabetes (n=8) 
and diabetes (n=15) groups, we merged the high CRP and very high CRP groups into one, called 
“elevated CRP.”  In the cognitively-intact cohort, no statistically significant interactions were detected 
between diabetes and CRP levels. However, in the CIND cohort, we found a statistically significant 
multiplicative interaction between diabetes and elevated CRP levels (p=0.047). Specifically, in 
participants with CIND, having diabetes and elevated CRP increases the risk of progressing to 
dementia by over 4-fold (HR 4.1, 95% CI: 1.15-14.22). This was particularly driven by poorly-
controlled diabetes (HR 13.6, 95% CI: 1.89-98) (Table 7). 
 
Table 7. Hazard ratios (HR) with 95% CI of progression to dementia for CIND cohort participants with 
normal and elevated CRP levels, by diabetes status. 
† Multi-adjusted for baseline age, sex, education, vascular risk factors (i.e. physical activity and BMI), 
heart disease, cerebrovascular disease, hypertension, and APOE ԑ4. 
 
Heart Disease-Free  Heart Disease 
n HR (95% CI) †  n HR (95% CI) † 
Diabetes-free 264 Reference  85 Reference 
Prediabetes 147 0.69 (0.42–1.14)  91 1.2 (0.58–2.3) 
Diabetes  35 0.71 (0.25–1.98)  49 2.5 (1.17–5.47) 
     HbA1c <7.5%  28 0.58 (0.18–1.90)  28 1.7 (0.63–4.38) 
     HbA1c ≥7.5% 7 1.4 (0.18–10.0)  21 5.8 (1.72–19.3) 
 
Normal CRP  Elevated CRP 
n HR (95% CI) †  n HR (95% CI) † 
Diabetes-free 278 Reference  71 Reference 
Prediabetes 178 0.67 (0.43-1.05)  60 2.0 (0.66-6.26) 
Diabetes  54 0.93 (0.48-1.79)  30 4.1 (1.15-14.22) 
     HbA1c <7.5%  45 0.71 (0.33-1.52)  11 0.84 (0.12-5.85) 
     HbA1c ≥7.5% 9 3.1 (0.86-11.07)  19 13.6 (1.89-98.0) 
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Given the elevated risk of progression to dementia in people with diabetes and (i) heart disease and 
(ii) elevated CRP, we additionally tested whether CRP levels modified the joint association between 
diabetes and heart disease in raising the risk of dementia. No additive interactions were detected 
between comorbid diabetes and heart disease and CRP levels (RERI= -0.88, 95% CI:-1.89-0.13, 
p=0.09). Furthermore, although the directionality of the HRs suggests a greater risk of dementia for 
the joint association of comorbid diabetes and heart disease plus high inflammation, no statistically 
significant associations between comorbid diabetes and heart disease and elevated CRP levels were 
detected (Table 8).   
 
Table 8. Hazard ratios (HR) with 95% CI of progression to dementia for CIND cohort participants with 
normal and elevated CRP levels, by diabetes and heart disease status. 
† Multi-adjusted for baseline age, sex, education, vascular risk factors (i.e. physical activity and BMI), 
cerebrovascular disease, hypertension, and APOE ԑ4. 
 
 
Normal CRP  Elevated CRP 
n HR (95% CI) †  n HR (95% CI) † 
No disease 219 Reference  45 Reference 
Diabetes only 27 0.36 (0.10-1.27)  8 1.7 (0.10-30.0) 
Heart disease only  59 1.1 (0.56-2.06)  26 1.4 (0.18-10.5) 
Diabetes and heart disease  27 1.7 (0.75-3.68)  22 4.1 (0.77-21.7) 
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D i s c u s s i o n  
In this large-scale, population-based longitudinal study of older adults followed for up to 15 years, we 
found that poorly-controlled diabetes was associated with double the risk of incident CIND and triple 
the risk of progression from CIND to dementia. The risk of progression to dementia was further 
exacerbated by the presence of heart disease and elevated levels of systemic inflammation in people 
with diabetes, particularly those with poor glycemic control. Our findings highlight diabetes 
(particularly poorly-controlled diabetes) and its cardiovascular complications as ideal targets for 
interventions to prevent cognitive impairment and dementia – conditions for which there is currently 
no available pharmacological treatment. 
The association of diabetes with cognitive impairment and its progression to dementia has been 
widely investigated in population-based studies of older adults, showing mixed findings. Five studies 
reported that diabetes is associated with incident cognitive impairment,60–63,66 while four studies did 
not observe such an association (Appendix 2).64,65,67,68 Similarly, as for diabetes’ role in progression 
from cognitive impairment to dementia, five studies reported an association, 64,70,72–74 whereas five did 
not (Appendix 3).61,69,71,75,76 Discrepancies in the literature could in part reflect methodological 
differences, particularly with regard to the assessment of diabetes (HbA1c, FPG, or oral glucose 
tolerance test [OGTT]), the duration of follow-up, and demographics of the study populations. 
Additionally, the majority of these studies did not take into account whether participants were above 
or below recommended thresholds for good glycemic control, omitting crucial information about the 
severity of diabetes within the study population.  
Our study, which examines degree of glycemic control in addition to general diabetes status, adds to 
this body of literature and may shed some light on its inconsistencies. We found that poorly-
controlled (HbA1c ≥7.5%) diabetes was associated with a greater risk of incident cognitive 
impairment and progression from cognitive impairment to dementia. Overall this indicates that the 
impact of diabetes on these adverse cognitive outcomes is exacerbated by higher levels of 
hyperglycemia.  
At the biological level, it is hypothesized that hyperglycemia could (i) directly degrade the myelin 
sheath of neurons, leading to signal processing dysfunction and neuronal death, and (ii) indirectly 
impair neural function by inducing microvascular and macrovascular changes in the brain.79 Together 
these contribute to micro-infarcts and brain atrophy, which lower the threshold for cognitive 
impairment and dementia to occur in response to other insults to the brain.79 Our results highlighting 
the exacerbating role of poor glycemic control on the associations between diabetes and these 
cognitive outcomes are consistent with this theoretical framework – people with poorly-controlled 
diabetes could have a higher risk of adverse cognitive outcomes because excessive hyperglycemia 
could lower the threshold for brain damage.  
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Notably, in the present study we found that prediabetes – a state characterized by only slight 
hyperglycemia – confers no additional risk of CIND or its progression to dementia compared with 
normoglycemia. This finding adds further support to the idea that the degree of hyperglycemia 
impacts the threshold at which adverse cognitive outcomes occur. Therefore, prediabetes could 
represent a crucial window of opportunity for reducing the risk of cognitive impairment (and ensuing 
dementia) that would come with progression to diabetes.  
It is plausible that interventions for diabetes prevention, aiming to restore normoglycemia, could also 
show benefits for cognitive impairment and dementia. Major clinical trials to prevent diabetes such as 
the Finnish Diabetes Prevention Study91 and the US Diabetes Prevention Program92 have 
demonstrated that intensive lifestyle modification (e.g. diet and exercise in a structured education 
program) can substantially and enduringly reduce the incidence of diabetes in people with prediabetes 
(-43% over 7 years and -27% over 15 years, respectively). Likewise, the recent Finnish Geriatric 
Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) demonstrates that a 
multi-domain intervention consisting of diet, exercise, cognitive training, and vascular risk monitoring 
can maintain or even improve cognitive function in older adults.93 However, to date, no studies have 
demonstrated the that the same multi-domain lifestyle-related intervention has simultaneous beneficial 
effects for both diabetes and cognitive impairment. Thus, future randomized controlled trials (RCTs) 
are needed to directly assess whether interventions for diabetes prevention also promote prevention of 
cognitive impairment and dementia.  
Our findings further highlight that diabetes does not act alone to increase the risk of cognitive 
impairment and its progression to dementia, but as part of a cluster of wider vascular disorders 
including heart disease. A large body of research focuses on the morbidity and mortality that results 
from the combined diagnoses of diabetes and heart disease, but comparatively little has been done to 
understand how the intersection of these diseases affects cognitive outcomes. To our knowledge, only 
one longitudinal study has previously assessed the risk of dementia associated with comorbid diabetes 
and heart disease (among other combinations of various vascular risk factors).94 This study reported a 
nearly 4-fold greater risk of “probable and possible Alzheimer’s disease” dementia in individuals with 
comorbid diabetes and heart disease (HR 3.7, 95% CI: 1.2-11.1) in a small sample (n=246).94  
In line with this finding, in our study heart disease acted synergistically with diabetes to exacerbate 
the risk of these adverse cognitive outcomes. In cognitively-intact participants, comorbid diabetes and 
heart disease more-than-doubled the risk of incident CIND, whereas neither diabetes nor heart disease 
alone had a significant impact. Furthermore, in participants with CIND, having diabetes and comorbid 
heart disease substantially increased the risk of dementia by 2.5-fold vs. heart disease alone (6-fold if 
diabetes was poorly-controlled).  
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The elevated risk of dementia with comorbid diabetes and heart disease is consistent with the 
emerging view that heart disease, like diabetes, is itself an independent risk factor for dementia. 
Observational studies have reported associations between dementia and specific cardiovascular 
conditions including coronary artery disease, MI, atrial fibrillation, valvular disease, and heart 
failure.95 Emerging evidence suggests that these diseases may affect the brain through not only via 
large-vessel disorders (e.g. stroke, coronary atherosclerosis) but also through small vessel disease.95,96 
All heart diseases in some way reduce cerebral blood flow, which can in turn worsen the brain’s 
vascular homeostasis, disrupt the blood-brain-barrier, and increase susceptibility to neurological 
insults.95 These mechanisms would exacerbate the detrimental effects of hyperglycemia to further 
lower the threshold for insults to the brain. Separately, the presence of heart disease in people with 
diabetes may also indicate greater diabetes severity, since this complication is more likely to emerge 
with longer diabetes duration and the increased exposure to oxidative stress and inflammation that 
characterizes poorly-controlled diabetes.97  
At the biochemical level, systemic chronic inflammation has been proposed as a key factor linking 
dementia with vascular disorders such as diabetes and heart disease.18,81,98 Inflammation contributes to 
the insulin resistance that leads to diabetes, and is further increased by disruptions in glucose 
metabolism once diabetes sets in.81,98 Over time, elevated concentrations of inflammatory mediators 
like CRP, IL-6, and fibrinogen can lead to cognitive impairment and dementia.18,98 In support of this 
hypothetical framework, our study highlights an interaction between diabetes and inflammation such 
that people with diabetes and elevated CRP levels have a 4-fold increased risk of progression from 
cognitive impairment to dementia. This soars to a nearly 14-fold increased risk with poorly-controlled 
diabetes.  
Strengths of this study include the longitudinal design with a long follow-up (up to 15 years), high 
participation rate (73% of those invited to the study), and relatively large sample size (n=2,508). 
Additional strengths include repeated measurements of cognitive functioning over the course of 
regular study visits, diagnosis of CIND through a comprehensive neuropsychological battery, and 
comprehensive assessment of diabetes status based on integration of data from Swedish national 
registries with clinical diagnoses collected by the examining physicians. Furthermore, our assessment 
of dementia status was corroborated by death certificates or medical records at hospital discharge in 
participants who died during follow-up. 
However, some limitations must be acknowledged. First, selection bias may have occurred because of 
nonresponse over follow-up, leading to a younger and relatively healthier sample. That said, number 
of people who dropped out of the study was small and, if anything, this would only underestimate the 
reported associations between diabetes, CIND, and dementia. Additionally, the biomarker used to 
define (pre)diabetes in the SNAC-K study, HbA1c, has comparably low sensitivity than FPG or 
OGTT, widely considered the gold standards for diabetes diagnosis.99  Thus, a proportion of diabetes 
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cases may not have been detected. These participants would have been misclassified as diabetes-free, 
leading to an underestimation of the associations presented in this thesis. Another limitation of this 
study is reduced statistical power when examining the impact of poorly-controlled diabetes, given the 
comparatively small sample size of participants (n=31 in the cognitively-intact cohort; n=28 in the 
CIND cohort). This would also contribute to an underestimation of the investigated associations. In 
addition, CRP is not an ideal measure of the chronic low-grade inflammation that is of interest in the 
context of diabetes, since CRP levels can be drastically altered in instances of acute inflammation 
such as infection.100 Future studies using other more specific inflammatory markers (e.g. interleukins) 
are warranted. Finally, we cannot rule out the influence of potential residual confounding due to 
unmeasured environmental, geographical, or stress-related factors.  
Our findings are generalizable to western populations with similar demographic characteristics as the 
SNAC-K population (i.e. urban and predominantly highly-educated Caucasians). With overall 
diabetes prevalence of 8.6%, it should be noted that our study population has markedly better 
metabolic health than the overall Swedish population aged ≥65 (diabetes prevalence estimated at 
15.6% in 2013),101 which is itself healthier than many other western nations – particularly the United 
States, where diabetes prevalence in people ≥65 is estimated at 22-33%.102 Considering this, plus the 
methodological issues outlined above that may underestimate the effect size, we believe the true 
extent to which diabetes increases the risk of cognitive aging – and the burden of this for society –  is 
even greater than our results suggest.  
In summary, this study provides evidence of an accelerated progression of cognitive decline (i.e. 
incident CIND and its worsening to dementia) with poorly-controlled diabetes. The presence of heart 
disease or high systemic inflammation in addition to diabetes further worsens the prognosis for 
cognitive impairment progressing to dementia.  
Future studies are needed to address synergistic interactions between mechanisms (e.g. 
hyperglycemic, inflammatory, or both) underlying the connection between diabetes, cognitive 
impairment, and dementia. Furthermore, turning toward solutions to fight the rise of diabetes-driven 
dementia, it is of great importance to determine whether diabetes prevention interventions also reduce 
the risk of cognitive impairment and dementia. Great public health significance lies in the possibility 
of addressing two of society’s most burdensome age-related diseases together with the same 
interventions.  
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Appendix 1—The cross-sectional relationship between diabetes and cognitive impairment  
Reference Study population Diabetes Cognitive 
impairment  
Results* Covariates† 
Kotsani et al, 2018 
Greece 
Population-based  
n = 403  
Aged ≥65 y  
Self-report 
Medical records 
HbA1c ≥6.5% 
 
MMSE score <26 
ICDT score <10 
OR 2.0 (1.2-3.4) 
 
OR 1.5 (1.0 – 2.4) 
Age, sex, education, 
ischemic heart disease, 
history of stroke or MI, 
depression, disability, TUG, 
self-rated health status, 
self-rated memory 
complaint  
Li et al 2018  
China 
Population-based  
n = 865  
Aged ≥55 y 
Medical records 
Medication use  
FPG ≥7.0 mmol/L 
MCI: Petersen (2004) OR 1.4 (0.91-2.19)  Age, sex, education, marital 
status, smoking, drinking, 
inactivity, hypertension, 
CHD, dyslipidemia, 
triglycerides, cholesterol  
Chen et al, 2016 
China 
Clinical–based 
multicenter 
n = 3988  
Aged ≥50 
Medical records MCI: MoCA score <26 OR 1.24 (1.03–1.50) Age, sex, education, marital 
status, smoking, physical 
activity, dyslipidemia, 
BMI≥25, hypertension 
Winkler et al, 2014 
Germany 
Population–based 
n = 1936  
Aged 50-80  
Self-report 
Medication use 
FPG ≥7.0 mmol/L 
no-FPG ≥11.0 mmol/L 
 
Undiagnosed 
diabetes was 
excluded 
 
 
MCI: Petersen (2004) 
amnestic MCI  
non-amnestic MCI 
Middle-age (50-65 yrs):  
MCI: OR 2.18 (1.38–3.43) 
aMCI: OR 2.33 (1.33–4.06) 
naMCI: OR 2.00 (1.07–3.73) 
 
Old-age (65-80 yrs):  
MCI: OR 1.09 (0.76–1.57) 
aMCI: OR 1.09 (0.69–1.71) 
naMCI: OR 1.10 (0.69–1.75) 
Age, sex, education, 
smoking, BMI, CVDs, 
hypertension, depression 
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Roberts et al, 2014 
USA 
Population–based 
n = 1437  
Aged 70-89  
Medication use 
Medical records 
FPG >126.0 mg/dL 
MCI: Petersen (2004)  OR 2.04 (1.09–3.81) Age, sex, education, 
smoking, obesity, 
hypertension, dyslipidemia, 
APOE ε4 
O´Bryant et al, 2013 
USA 
Two population–based: 
 
FRONTIER 
n = 509  
Aged ≥40  
 
TARCC 
n = 1098  
Aged ≥50 
Self-report 
Medication use 
FPG >126.0 mg/dL 
MCI: Petersen (2004)  FRONTIER: 
OR 1.99 (1.09–3.81) 
 
TARCC: 
OR 1.13 (0.71–1.78) 
Age, sex, education, 
obesity, hypertension, 
hyperlipidemia, depressive 
symptoms, APOE ε4 
Atti et al, 2010 
Italy 
Population–based 
n = 7389  
Aged ≥60 
Self-report 
Medical records 
Clinical examinations 
CIND: 
<2 SDs of the 
adjusted MMSE 
mean of dementia-
free participants  
OR 1.62 (1.18–2.21) Age, sex, education, marital 
status, SES, vascular risk 
factors (smoking, alcohol, 
BMI), medical conditions 
Roberts et al, 2008 
USA 
Population–based 
case–control 
n = 1969  
Aged ≥70 
Self-report 
Medication use 
Medical records 
FPG ≥126.0 mg/dL 
no-FPG ≥114.0 
mg/dL 
MCI: Petersen (2004) 
amnestic MCI  
non-amnestic MCI 
OR 1.33 (0.98–1.81) Age, sex, education,  
smoking, BMI, hypertension, 
stroke/TIA 
 
* Results are reported as Odds Ratio (95% Confidence intervals). Reference group included diabetes-free participants. Bold indicates the presence of an association.  
Abbreviations: aMCI, amnestic mild cognitive impairment; APOE ε4, Apolipoprotein ε4 allele; BMI, body mass index; CIND, cognitive impairment-no dementia; CVDs, cardiovascular disease; FPG, fasting 
plasma glucose; no-FPG, non-fasting plasma glucose; MCI, mild cognitive impairment; MoCA, Montreal Cognitive Assessment; naMCI, non-amnestic mild cognitive impairment; OR, odds ratio; SD, 
standard deviation; SES, socioeconomic status; TIA, transient ischemic attack 
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Appendix 2—The longitudinal relationship between (pre)diabetes and cognitive impairment  
Reference Study population Follow-up Diabetes Cognitive Impairment Results* Covariates 
Rawlings et al, 2019 
USA 
Clinical-based 
multicenter (ARIC) 
n = 5,099   
Aged 69-88  
5 years Self-report 
Medication use 
HbA1c ≥6.5% 
MCI: Petersen (2004) HR 1.14 (1.00-1.31) 
     A1c ≥7%: HR 1.38 (1.12-1.69) 
     A1c <7%: HR 1.05 (0.91-1.22) 
 
 
Age, race, sex, 
education, drinking, 
smoking, hypertension, 
APOE ε4, history of 
stroke, history of CHD  
 
Ng et al, 2016 
Singapore 
Population–based 
n = 1,519  
Aged ≥55  
3 years Self-report 
Medication use 
 
MCI: Petersen (2004) HR 2.84 (1.92–4.19) 
 
Age, sex, education, 
smoking, physical, 
social, productive 
activities score,  APOE 
ε4 
Roberts et al, 2014 
USA 
Population–based  
n = 1,450  
Aged ≥70 
4 years Medication use 
Medical records 
FPG ≥126.0 
mg/dL 
MCI: Petersen (2004) 
amnestic MCI  
non-amnestic MCI 
HR 1.42 (1.06–1.91) 
aMCI: HR 1.58 (1.12–2.25) 
naMCI: HR 1.28 (0.72–2.25) 
Age, sex, education, 
BMI≥30, moderate 
exercise, CVDs, 
hypertension, 
dyslipidemia, depression, 
statins, APOE ε4 
Ganguli et al, 2013 
USA 
Population–based  
n = 1,636  
Aged ≥65 
4 years Self-report 
HbA1c ≥6.0% 
 
MCI: cognitive domains 
score <1 SD of 
normative mean  
HR 1.51 (1.04–2.20) Age, sex, education, 
attrition bias 
Xu et al, 2010 
Sweden 
Population–based  
n = 963 
Aged ≥75 
4.8 years Self-report 
Medication use 
Medical records 
no-FPG ≥11.0 
mmol/L 
MCI: Petersen (2004)  Prediabetes: 
HR 1.1 (0.4–2.7) 
 
Diabetes: 
HR 1.0 (0.4–2.8) 
Age, sex, education, 
baseline MMSE, BMI, 
CVDs, survival status,   
APOE ε4 
Panza et al, 2008 
Italy 
Population–based  
n = 1,445  
Aged ≥65 
7.6 years Self-report 
Medication use 
Medical records 
FPG ≥ 140 
mg/dL 
MCI: Petersen (1999) 
SMC not taken into 
account 
RR 1.1 (0.7–1.4) 
 
Age, sex, education, 
smoking, total cholesterol, 
CVDs, hypertension  
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Luchsinger et al, 2007 
USA 
Population–based  
n = 918  
Aged ≥65 
6.1 years Self-report 
Medication use 
MCI: Petersen (1999)  
amnestic MCI  
non-amnestic MCI 
HR 1.4 (1.0–1.8) 
aMCI: HR 1.5 (1.0–2.2) 
naMCI: HR 1.28 (0.9–1.8) 
Age, sex, education, 
ethnicity, smoking, CVDs, 
hypertension, LDL-c, 
APOE ε4 
Yaffe et al, 2004 
USA, Canada 
Population–based 
n = 4,961 women 
Aged >60 
4 years Self-report 
Medication use 
FPG ≥ 7.0 
mmol/L 
MCI: Petersen (1999) Prediabetes: 
OR 1.06 (0.51–2.20) 
 
Diabetes: 
OR 1.78 (0.99–3.20) 
Age, treatment 
Solfrizzi et al, 2004 
Italy 
Population–based 
n = 1,524 
Aged >65 
3.5 years Self-report 
Medication use 
Medical records 
FPG ≥ 7.8 
mmol/L 
MCI: Petersen (1999) 
SMC not taken into 
account; non-cognitive 
disabilities and 
comorbidities included 
No association (not reported) Age, sex, education, 
smoking, CVDs, 
hypertension, total 
cholesterol, HDL-c 
 
* Results are reported as Hazard Ratio (95% Confidence intervals). Reference group included diabetes-free participants. Bold indicates the presence of an association.  
Abbreviations: aMCI, amnestic mild cognitive impairment; APOE ε4, Apolipoprotein ε4 allele; BMI, body mass index; CIND, cognitive impairment-no dementia;  CHD, chronic heart disease; CVDs, 
cardiovascular disease; FPG, fasting plasma glucose; no-FPG, non-fasting plasma glucose; HbA1c, glycated hemoglobin; HR, hazard ratio; HDL-c, high density lipoprotein cholesterol; LDL-c, low density 
lipoprotein cholesterol; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; naMCI, non-amnestic mild cognitive impairment; OR, odds ratio; RR, relative risk; SD, standard deviation; 
SES, socioeconomic status; SMC, subjective memory complains
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Appendix 3—The relationship between (pre)diabetes and the progression from cognitive impairment to dementia 
Reference Study population Follow-
up   
Diabetes Cognitive Impairment 
and Dementia 
Results* Covariates† 
Rawlings et al, 2019 
USA 
Clinical-based 
multicenter (ARIC) 
n = 5,099  
Aged 69-88 
5 years Self-report 
Medication use 
HbA1c ≥6.5% 
MCI: DSM-V 
 
Dementia: DSM-V 
 
HR 1.15 (0.90-1.47) 
     A1c ≥ 7%: 1.38 (0.96-2.00) 
     A1c  <7%: 1.02 (0.78-1.35)  
Age, race, sex, 
education, drinking, 
smoking, hypertension, 
APOE4, history of stroke, 
history of CHD 
Ganguli et al, 2019 
USA 
Population-based  
n = 356  
Aged ≥65 
5 years Self-report MCI: CDR score 0.5-1 
 
Dementia: CDR score >1 
RR 1.31 (0.94-1.68) 
 
“Adjusted for 
demographic 
characteristics” 
Ng et al, 2016 
Singapore 
Population–based 
n = 2042 
Aged ≥55  
3 years Self-report 
Medication use 
 
MCI: Petersen (2004) 
 
Dementia: DSM-IV   
HR 2.5 (1.9–4.2) Age, sex, education, 
smoking, physical, social, 
productive activities 
score, APOE genotype 
Viticchi et al, 2012 
Italy 
Clinical–based 
n = 117  
Mean age 75.7 
1 year Self-report 
Medication use 
FPG >7.0 
mmol/L 
MCI: Petersen (2001) 
 
Dementia: DSM-IV 
 
Dementia: OR 1.3 (0.4–4.7) Age, sex, education, 
smoking, carotid plaques,  
hypertension, baseline 
cognition, cerebrovascular 
reactivity 
Li et al, 2012 
China 
Clinical–based 
n = 257  
Aged ≥60 
3 years FPG >7.0 
mmol/L 
MCI: Petersen (2011) 
 
Dementia: DSM-IV 
AD: NINCS-ADRDA 
Dementia: HR 2.4 (1.1–5.3) 
 
AD: HR 2.9 (1.1–7.6) 
Not specified 
Li et al, 2011 
China 
Population–based  
n = 837  
Aged ≥55 
5 years Medical records 
Medication use 
MCI: Petersen (1999) HR 1.6 (1.0–2.6) Age, sex, education, 
occupation, ADL, 
depression, APOE4, 
baseline MMSE  
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Xu et al, 2010 
Sweden 
Population–based  
n = 1098 
Aged ≥75 
4.8 years Self-report 
Medical records 
Medication use 
no-FPG ≥11.0 
mmol/L 
MCI: Petersen (2004) 
 
Dementia: DSM-III-R 
AD: NINCS-ADRDA 
Prediabetes 
Dementia: HR 5.0 (2.3–10.1) 
AD: HR 5.7 (2.4–13.5) 
 
Diabetes 
Dementia: HR 2.9 (1.3–6.3) 
AD: HR 2.8 (1.2–6.8) 
Age, sex, education, 
baseline cognition, BMI, 
CVDs, hypertension, 
survival status,  APOE 
genotype 
Velayudhan et al, 2010 
UK 
Population–based  
n = 103 
Aged ≥65 
4 years Self-report 
Medical records 
Medication use 
 
MCI: Petersen (1999) 
 
Dementia: DSM-IV 
HR 2.9 (1.1–7.3) Age, sex, education, 
baseline cognition, VRFs 
(smoking, alcohol, BMI), 
CVDs, depression, 
APOE4, diabetes duration 
Artero et al, 2008 
France 
Population–based  
n = 2882 
Aged ≥65 
4 years Self-report 
 
MCI: Petersen (1999) 
 
Dementia: DSM-IV 
 
Not significant (not reported) Not reported 
Ravaglia et al, 2006 
Italy 
Clinical–based 
n = 165  
Aged ≥60 
2.8 years Self-report 
Medical records 
MCI: Petersen (2004) 
 
Dementia: DSM-IV 
 
HR 0.8 (0.3–2.1) Age, sex, education 
 
* Results are reported as Hazard Ratio (95% Confidence intervals). Reference group included diabetes-free participants. Bold indicates the presence of an association. 
Abbreviations: AD, Alzheimer’s disease; ADL, activities of daily living; aMCI, amnestic mild cognitive impairment; APOE ε4, Apolipoprotein ε4 allele; BMI, body mass index; CIND, cognitive impairment-no 
dementia; CHD, chronic heart disease; CVDs, cardiovascular disease; DSM, Diagnostic and Statistical Manual of Mental Disorders; FPG, fasting plasma glucose; no-FPG, non-fasting plasma glucose; 
HbA1C, glycated hemoglobin; HR, hazard ratio; LDL-c, low density lipoprotein cholesterol; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; naMCI, non-amnestic mild cognitive 
impairment; NINCS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke & Alzheimer’s Disease and Related Disorders Association; OR, odds ratio; RR, relative risk; SD, 
standard deviation; SES, socioeconomic status; SMC, subjective memory complains; TIA, transient ischemic attack; VRFs, vascular risk factors 
 
 
